Table 3.

Absolute and relative risk of treatment-emergent inpatient and outpatient claims associated with diagnoses of pancreatic and thyroid neoplasm among exenatide and metformin or glyburide initiators, Normative Health Information database, 1 June 2005−31 December 2009.

	Cases (N)	Patients (N)	Absolute risk (%)	Relative risk	95% CI
Cases identified from inpatient or outpatient claims
All thyroid neoplasms
Exenatide	46	32,807	0.1	1.2	0.7–1.8
Metformin/glyburide	40	32,828	0.1	1	reference
Benign thyroid neoplasms
Exenatide	11	32,877	0	0.7	0.3–1.7
Metformin/glyburide	15	32,879	0	1	reference
Thyroid malignancies
Exenatide	37	32,822	0.1	1.4	0.8–2.4
Metformin/glyburide	26	32,842	0.1	1	reference
Pancreatic malignancy
Exenatide	21	32,889	0.1	0.8	0.5–1.6
Metformin/glyburide	25	32,878	0.1	1	reference
Cases identified from inpatient claims only
All thyroid neoplasms
Exenatide	7	32,894	0.0	0.7	0.2–2.0
Metformin/glyburide	10	32,894	0.0	1.0	reference
Benign thyroid neoplasms
Exenatide	0	32,894	0.0	0.0	0.0–4.1
Metformin/glyburide	2	32,894	0.0	1.0	reference
Thyroid malignancies
Exenatide	7	32,894	0.0	0.9	0.3–2.6
Metformin/glyburide	8	32,894	0.0	1.0	reference
Pancreatic malignancy
Exenatide	12	32,894	0.0	0.5	0.2–1.1
Metformin/glyburide	23	32,894	0.1	1.0	reference

CI, confidence interval.